uniQure (NASDAQ:QURE) Shares Up 5% – Here’s What Happened

uniQure N.V. (NASDAQ:QURE) shares shot up 5% during mid-day trading on Friday . The company traded as high as $23.32 and last traded at $23.0850. 314,187 shares changed hands during trading, a decline of 83% from the average session volume of 1,837,140 shares. The stock had previously closed at $21.98.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Chardan Capital reiterated a “buy” rating and set a $53.00 price target on shares of uniQure in a research report on Thursday, December 4th. UBS Group set a $95.00 price objective on shares of uniQure in a research note on Thursday, September 25th. William Blair reiterated a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Mizuho reduced their price target on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, December 8th. Finally, HC Wainwright decreased their price target on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $60.82.

uniQure Trading Up 4.5%

The stock has a 50 day moving average of $24.87 and a 200 day moving average of $27.65. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The firm has a market cap of $1.43 billion, a P/E ratio of -5.23 and a beta of 0.68.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. As a group, equities research analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other uniQure news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 102,247 shares of company stock valued at $2,839,298 in the last ninety days. 4.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of QURE. Private Trust Co. NA bought a new position in uniQure during the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp boosted its stake in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. CIBC Private Wealth Group LLC bought a new position in shares of uniQure in the third quarter worth approximately $50,000. FNY Investment Advisers LLC increased its stake in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.